EUROIMMUN
a PerkinElmer company

Medizinische
Labordiagnostika
AG

SARS-CoV-2 neutralisation test in ELISA format

SARS-CoV-2 NeutraLISA

- Surrogate virus neutralisation test (sVNT) for the determination of neutralising antibodies that inhibit the binding of SARS-CoV-2 S1/RBD to ACE2 receptors, thus preventing the virus from entering the host cell
- Supports the evaluation of the individual immune response after SARS-CoV-2 infection or vaccination with S1/RBD-based vaccines
- High specificity (99.7 %) and sensitivity (95.9 %)
- Very high agreement of results compared with a plaque reduction neutralisation test ($PRNT_{50}$)
- Established ELISA method – suitable for routine laboratory diagnostics, no BSL-3 laboratory required
- Automatable even for high-throughput analysis, results available in 2 hours
- Multispecies test – application with animal samples possible for research use

Order number: EI 2606-9601-4

EUROIMMUN Medizinische Labordiagnostika AG · Seekamp 31 · 23560 Lübeck (Germany) · Phone: +49 451 2032-0 · info@euroimmun.de · www.euroimmun.com



Test principle

- Modelled upon nature: Neutralising antibodies in the sample compete with the host-cell receptor (ACE2) for the binding to S1/RBD in the first incubation step – no preadsorption required
- The more neutralising antibodies inhibit the binding of the biotinylated ACE2 to S1/RBD, the weaker is the colour reaction of the sample
- In contrast to classic antibody testing, only immunoglobulins with an inhibitory effect on the ACE2 S1/RBD binding are detected, but no other antibodies

Method comparison

74 samples from patients with past confirmed SARS-CoV-2 infection		EUROIMMUN SARS-CoV-2 NeutraLISA	
		positive	negative
SARS-CoV-2 $PRNT_{50}$	positive	71	0
	negative	1	2

98.6 % agreement